FDA Brief

Warning letters Devices

FDA warning letter to

Specialty Health Products CO, LLC

High riskIssued Jul 7Posted Sep 22Center for Devices and Radiological Health

Specialty Health Products was cited for quality-system, unapproved marketing, and listing violations for its Hydro-San and Aqua Cleanse colonic irrigation devices.

What happened

FDA inspected the Phoenix, AZ facility from December 1 to December 11, 2025 and found violations of the Quality System regulation, the device CGMP rule. FDA also reviewed the website, user guide, catalog, and written orders, and on June 30, 2026 reviewed FDA’s device identifier database (GUDID); it found the Hydro-San Plus marketed for colon hydrotherapy without clearance or approval and missing required device identifier and listing information. The firm’s multiple responses were not adequate.

What FDA found

  1. The firm did not validate design for biocompatibility or the claimed 7-year shelf life of the Class II colonic irrigation devices.

    21 CFR 820.30(g)
  2. The firm could not show engineering change orders or approvals for multiple Hydro-San Plus design changes, including valve changes and an added component.

    21 CFR 820.30(i)
  3. Production instructions for Aqua Cleanse lacked testing steps, parameters, and acceptance criteria, and disinfection procedures did not include the disinfectant maker’s required contact times, dilution, or verification.

    21 CFR 820.70(a)
  4. Eight complaints were not formally evaluated or investigated, and some complaints were not recorded in the complaint log or forms.

    21 CFR 820.198(a)
  5. A servicing procedure contained the text of another procedure, and controlled documents were editable, unsigned, or undated without controls against unauthorized changes.

    21 CFR 820.40
  6. The Hydro-San Plus was promoted for colon hydrotherapy and changed without required premarket clearance or approval, and the firm had not listed the modified device or related speculum kits or submitted required unique device identifier information to FDA’s database.

    21 U.S.C. § 351(f)(1)(B); 21 CFR 807.81(a)(3)(ii); 21 U.S.C. § 360(j); 21 CFR 801.20(a); 21 CFR 830.300(a)

What FDA wants

FDA asks the firm to stop activities that cause misbranding or adulteration and to respond in writing within 15 business days with the specific corrections, corrective actions, and a timetable for any work not yet complete.

Who should pay attention

  • clinics and wellness centers that buy or use colonic irrigation devices
  • distributors and importers of speculum kits
  • quality teams at device makers that rely on design and complaint records

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Olympus Medical Systems Corporation

    FDA warns Olympus over quality-system failures across six medical device plants, including unvalidated designs and released nonconforming devices.

    High risk
  2. Unilam Co., LTD

    Unilam Co., LTD's UV sunlamps violate quality-system and radiation-safety testing rules, FDA says.

    High risk
  3. ZOLL Medical Corporation

    FDA warned ZOLL Medical after an inspection found quality-system, design-validation, supplier, and reporting failures for defibrillators, ventilators, and electrodes.

    High risk
  4. Abbott Diabetes Care, Inc.

    FDA warns Abbott Diabetes Care that FreeStyle Libre 3 glucose monitors lacked design transfer and finished-device accuracy release testing.

    High risk